Calcineurin inhibitors such as cyclosporin A (CsA) are the mainstay of immunosuppressive treatment for organ transplant recipients. Squamous cell carcinoma (SCC) of the skin is a major complication of treatment with these drugs, with a 65 to 100-fold higher risk than in the normal population 1 . By contrast, the incidence of basal cell carcinoma (BCC), the other major keratinocyte-derived tumour of the skin, of melanoma and of internal malignancies increases to a significantly lesser extent 1 . Here we report that genetic and pharmacological suppression of calcineurin/nuclear factor of activated T cells (NFAT) function promotes tumour formation in mouse skin and in xenografts, in immune compromised mice, of H-ras V12 (also known as Hras1)-expressing primary human keratinocytes or keratinocytederived SCC cells. Calcineurin/NFAT inhibition counteracts p53 (also known as TRP53)-dependent cancer cell senescence, thereby increasing tumorigenic potential. ATF3, a member of the 'enlarged' AP-1 family, is selectively induced by calcineurin/NFAT inhibition, both under experimental conditions and in clinically occurring tumours, and increased ATF3 expression accounts for suppression of p53-dependent senescence and enhanced tumorigenic potential. Thus, intact calcineurin/NFAT signalling is critically required for p53 and senescence-associated mechanisms that protect against skin squamous cancer development.
The selectively increased risk of SCC formation in CsA-treated patients 1 indicated that calcineurin signalling, central to keratinocyte growth/differentiation control [2] [3] [4] , has an intrinsic role in keratinocyte tumour suppression. Mice with keratinocyte-specific deletion of the calcineurin B1 gene (CnB1, also known as Ppp3r1), essential for calcineurin activity 3 , have increased susceptibility to chemically induced carcinogenesis, with decreased latency, higher incidence and size of tumours, and earlier malignant conversion ( Fig. 1a and Supplementary Fig. 1 ).
To assess the relevance of these findings to human skin, primary human keratinocytes (HKCs) were infected with an oncogenic H-ras V12 -transducing retrovirus, followed by skin-reconstitution grafting assays onto immune compromised (Scid) mice. In control mice, H-ras V12 -expressing HKCs produced an acanthotic epithelium with normal pattern of differentiation. In CsA-treated mice, grafted cells gave rise to tumours with disordered proliferation and histopathological features of moderately to poorly differentiated SCC ( Fig. 1b and Supplementary Fig. 2a ). Similar results were obtained by cell injection at the dermal-epidermal junction, that is, a location approximating that of malignant skin tumour formation. H-ras V12 -expressing HKCs formed only differentiated epidermal cysts in control animals, whereas in animals treated with CsA or the unrelated calcineurin inhibitor FK506, they produced highly cellular lesions with decreased differentiation ( Fig. 1c and Supplementary Fig. 2b ). Similar lesions were produced by H-ras V12 -expressing HKCs with siRNA-mediated knockdown of the CnB1 gene ( Fig. 1c and Supplementary Fig. 2c ), and in mice treated with a calcineurin/NFAT inhibitory peptide (VIVIT) 5 versus control scrambled peptide (VEET) ( Supplementary Fig. 2d-f ).
Cutaneous SCCs are characterized by mutation and/or decreased expression of p53, but only 10-20% have ras mutations 6 , raising the question of the relevance of the present findings for cancer cells without ras activation. Nucleotide sequencing showed that SCC12 and SCC13 cells, two independent lines from cutaneous SCC with poorly aggressive properties 7 , have wild-type ras genes and, as reported 8, 9 , single p53 missense mutations. Upregulation of endogenous p53 in these cells still induces 'canonical' effectors like p21 WAF1/Cip1 (also known as CDKN1A; ref. 10), possibly through an indirect mechanism like the reported ability of mutant p53 to bind and titrate p63 (also known as TRP63; refs 11, 12), a negative regulator of p21 expression and senescence in keratinocytes 13, 14 . Injection of SCC12 and SCC13 cells at the dermal-epidermal junction resulted in differentiated cysts. By contrast, in mice treated with CsA or VIVIT, or as a consequence of p53 knockdown, SCC cells formed highly cellular and moderately differentiated infiltrating tumours ( Supplementary Figs 3 and 4a ).
Cancer cell senescence is a failsafe mechanism against tumour development 15 that can be associated with increased expression of terminal differentiation markers 16 . Staining for senescence-associated b-galactosidase activity (SA-b-Gal) 17 was positive in lesions formed by H-ras V12 -expressing HKCs or SCC13 cells in control, but not in CsAtreated mice ( Fig. 1d and Supplementary Fig. 5a ). This was paralleled by differences in Ki67 and K1 (also known as MKI67 and CAMK1D, respectively) differentiation marker expression ( Supplementary Fig. 6 ). Similarly decreased SA-b-Gal staining was found in tumours formed by ras-expressing HKCs with knockdown of CnB1 or, as predicted from the literature, of p53, a key mediator of oncogene-induced senescence 15 (Fig. 1e and Supplementary Fig. 5b ). Senescence was also suppressed in tumours formed by SCC13 cells with p53 knockdown ( Supplementary Fig. 4b, c ).
H-ras V12 -induced senescence of cultured cells was also counteracted by CsA or VIVIT treatment and p53 knockdown ( Supplementary  Fig. 7a -c). Induction of terminal differentiation markers was similarly suppressed ( Supplementary Fig. 7d ). Paralleling these changes and consistent with previous reports 15 , oncogenic ras expression caused increased p53 protein levels, without effects on transcription ( Supplementary Fig. 7e ). Importantly, calcineurin/NFAT inhibition counteracted the ras effects suppressing p53 expression not only at the protein, but also at the mRNA level ( Supplementary Fig. 7e ).
In HKCs and SCC cells, p53 gene transcription is under negative control of the AP-1 complex, specifically c-Jun and c-Fos 10 (also Supplementary Fig. 8a -c). c, HKCs infected with retroviruses expressing constitutively active NFATC1 (1) 19 or GFP control (2) plus/minus subsequent CsA treatment were analysed for ATF3 expression. Similar results were obtained by real time RT-PCR ( Supplementary Fig. 8f ). d, HKCs plus/minus CsA/VIVIT treatment and cycloheximide (CHX) exposure were analysed at various times (hours) for Atf3 expression by real-time RT-PCR. Error bars represent mean 6 s.d. (n 5 3 replicates). e, Extracts of HKCs plus/ minus CsA treatment or Nfatc1 knockdown (left panel) or intact human epidermis (right panel) were processed for chromatin immunoprecipitation with anti-NFATC1 antibodies or non-immune IgGs, followed by real-time PCR of Atf3 promoter regions containing and lacking high-affinity NFATC1 binding sites (black and white boxes in the map above). Chromatin immunoprecipitation assays of the NFAT-binding region of the calcipressin (Rcna1) gene 20 , and a b-actin genomic region without NFAT binding sites were included. f, SCCs from three patients under CsA treatment and from untreated patients (Untr) from the general population were analysed by immunoblotting for ATF3 expression, in parallel with HKCs infected with an ATF3-expressing retrovirus (ATF3) versus empty vector control. Similar differences in Atf3 mRNA expression were observed with an independent set of patients ( Supplementary Fig. 9a ). g, Tissue arrays of cutaneous SCCs from patients under CsA treatment versus general untreated population (Untr) were analysed for ATF3 expression by immunohistochemistry. Representative staining is shown along with quantification of ATF3-positive nuclei in each visual field of tumour tissues. Error bars represent mean 6 s.d. (n 5 18, 16, 126 and 127 tumours per group, from left to right).
known as JUN and FOS, respectively). Real time PCR with reverse transcription (RT-PCR) and immunoblotting showed that c-Jun and c-Fos levels were unaffected by CsA or VIVIT treatment of HKCs. By contrast, expression of ATF3, a member of the 'enlarged' AP-1 family previously connected with SCC progression 18 , was sharply upregulated ( Fig. 2a and Supplementary Fig. 8a ). ATF3 expression also increased after CnB1 or Nfatc1 knockdown ( Fig. 2b and Supplementary Fig. 8b ,c), and in SCC13 cells treated with CsA or VIVIT ( Supplementary Fig. 8d ). Enhanced ATF3 expression in CsA-or VIVIT-treated keratinocytes was paralleled by increased binding of the ATF3 protein to specific oligonucleotide sequences of the p53 promoter containing intact, but not mutated, ATF3 binding sites ( Supplementary Fig. 8e ). Increased ATF3 expression in CsA-treated keratinocytes was suppressed by retrovirally expressed constitutively active NFATC1 (ref. 19 ; Fig. 2c and Supplementary Fig. 8f ). The kinetics of Nfatc1 knockdown and ATF3 upregulation were highly correlated ( Supplementary Fig. 8g ), and induction of ATF3 by CsA or VIVIT occurred to similar or greater extent when protein synthesis was inhibited ( Fig. 2d ). Consistent with ATF3 being a direct target, chromatin immunoprecipitation assays showed binding of endogenous NFATC1 to two distinct regions of the Atf3 promoter harbouring NFAT binding sites, such binding being abolished by Nfatc1 knockdown or CsA treatment ( Fig. 2e , left panel). In intact human epidermis, we also detected NFATC1 binding to the Atf3 promoter comparable to a well established NFATC1 target, the calcipressin gene (Rcna1) 20 ( Fig. 2e , right panel).
CsA treatment caused ATF3 upregulation and p53 down-modulation also in human skin explants and tumour xenografts ( Supplementary  Fig. 8h , i). Increased ATF3 and decreased p53 expression was also observed in SCCs from CsA-treated patients versus untreated patients, together with decreased senescence ( Fig. 2f and Supplementary Fig. 9 ). Increased ATF3 expression in SCCs from CsA-treated patients was further confirmed by tissue array/immunohistochemical analysis of a cohort of tumour biopsies (Fig. 2g ). Nucleotide sequence analysis of p53 in five SCCs from CsA-treated patients revealed missense mutations affecting the DNA-binding domain and/or polymorphisms associated with cancer development (72 Pro/Arg substitution) similar to those in the general patient population (http://www-p53.iarc.fr).
Functionally, ectopic ATF3 expression, at levels comparable to those occurring in SCCs from CsA-treated patients (Fig. 2f ), blocked expression of p53 and senescence-associated genes (Fig. 3a, b) . Conversely, ATF3 knockdown induced these genes, counteracting the CsA and VIVIT effects (Fig. 3c,d and Supplementary Fig. 10 ). In vivo, ectopic ATF3 promoted tumorigenicity of H-ras V12 -expressing HKCs and SCC cells, producing aggressive tumours with reduced senescence as those caused by calcineurin/NFAT inhibitors (Fig. 3e, f and Supplementary Fig. 11a , b, e). Conversely, Atf3 knockdown overcame the tumour-promoting effects of these compounds and restored senescence (Fig. 3g, h and Supplementary Fig. 11c, d) .
Senescence serves to restrict tumorigenic potential of cells 15 . To test whether calcineurin inhibition exerts opposite effects, H-ras V12expressing HKCs were sorted for elevated integrin a6 and low CD71 levels (a6 bri CD71 dim cells), enriching for cells with high self-renewal potential 21 . In culture, response of a6 bri CD71 dim cells to VIVIT and CsA treatment, in term of ATF3 and p53 levels, was similar to that of total unsorted populations (data not shown). To assess their in vivo behaviour, H-ras V12 -expressing a6 bri CD71 dim cells were injected in serial dilutions, together with constant amount of normal HKCs, into Supplementary Fig. 10a . d, HKCs plus/minus H-ras V12 expression, Atf3 knockdown and CsA treatment as indicated were analysed for ATF3 and p53 expression by immunoblotting. For densitometric quantification and experimental conditions see Supplementary Fig. 10b . e, f, H-ras V12expressing HKCs (e) or SCC13 cells (f) infected with ATF3-expressing and control retroviruses were injected at the dermal-epidermal junction of Scid mice. Shown are histological images of lesions recovered 6 weeks later. For quantification see Supplementary Fig. 11a, b . g, H-ras V12 -expressing HKCs plus/minus Atf3 knockdown were injected at the dermal-epidermal junction of Scid mice, followed by CsA treatment. Mice were killed 10 days later. For histological images see Supplementary Fig. 11c . h, Lesions from the previous experiment were analysed for SA-b-Gal activity. Low magnification images and quantification are shown in Supplementary Fig. 11d .
NOD/SCID interleukin-2 receptor gamma chain null (Il2rg 2/2 ) mice 22 . Addition of Matrigel allowed retention of injected cells in well identifiable 'nodules'. Histological analysis of nodules from control mice at 1 month after injection showed that H-ras V12 -expressing HKCs injected in low number formed only a few keratinized cysts with limited cellularity. By contrast, in nodules recovered from CsAtreated mice there was a striking number of 'proliferative centers', composed of keratinocytes with elevated Ki67 positivity (Fig. 4a, b and Supplementary Fig. 12 ). When injected in higher number, H-ras V12 -expressing HKCs formed highly keratinized and poorly proliferative cysts in control mice, whereas in CsA-treated animals they gave rise to overt tumours (Fig. 4c) . Similar results were obtained with sorted H-ras V12 -and ATF3-expressing HKCs versus controls (Fig. 4b,c ). Established cancer cell lines, including SCC cells, also contain distinct sub-populations with different growth/tumorigenic potential 23, 24 . SCC13 cells plus/minus increased ATF3 expression were sorted for elevated integrin a6 and low CD71 levels or for expression of CD133, a cell surface marker of putative cancer stem cell populations, including keratinocyte-derived 24 . Sorting resulted in .20-fold enrichment of tumorigenic cells. As few as 500 sorted SCC13 cells overexpressing ATF3 produced detectable tumours, whereas larger numbers of control cells were required ( Fig. 4d and Supplementary  Fig. 13a ). Histologically, even the lowest number of ATF3-expressing cells produced highly cellular tumours with poor differentiation, whereas control cells formed differentiated cystic lesions (Fig. 4d, e and Supplementary Fig. 13a, b) .
In further testing, as little as 1,000 freshly dissociated cells from tumours formed by H-ras V12 -expressing HKCs in CsA-treated mice gave rise to secondary tumours, whereas substantially higher cell numbers were required under control conditions (Fig. 4f) . Similar results were obtained with H-ras V12 -expressing HKCs or SCC13 cells plus/minus increased ATF3 expression ( Fig. 4f, g) . Histologically, secondary tumours formed in CsA-treated mice or by ATF3-expressing cells were highly cellular and poorly differentiated, whereas those under control conditions consisted, as the primary tumours, of differentiated cysts (Fig. 4f, g and Supplementary Fig. 14) .
Many regulatory pathways, including calcineurin/NFAT [2] [3] [4] 25 , have both growth-promoting and -suppressing functions, depending on cell type and context. An impact on tumour growth has been recently attributed to calcineurin via indirect effects on angiogenesis 26, 27 Supplementary Fig. 12a, b. d, e, Sorted a6 bri CD71 dim populations of SCC13 cells plus/minus ATF3 overexpression were injected in the indicated numbers into Scid mice. Shown are quantification of the results and representative histological images. Experimental conditions were the same as with CD133 sorted cells ( Supplementary Fig. 13 ). f, g, Cells dissociated from tumours formed by H-ras V12 -HKCs in mice plus/minus CsA treatment, or with ATF3 overexpression (f) or from tumours formed by SCC13 cells plus/minus ATF3 overexpression (g) were injected in decreasing numbers into secondary recipient mice (Scid), with tissue retrieval 4 weeks later. For representative images and experimental conditions see Supplementary Fig. 14. NATURE | Vol 465 | 20 May 2010 LETTERS here is based on calcineurin/NFAT suppression of ATF3, a negative regulator of p53. The resulting impact on keratinocyte cancer cell senescence versus growth is likely of clinical significance for the many patients under treatment with calcineurin inhibitors as immunosuppressants 1 , and may be of relevance for other cancer types where altered calcium signalling has a role 28 .
METHODS SUMMARY
Multistep skin carcinogenesis assays were performed with mice with keratinocyte-specific deletion of the CnB1 gene (CnB1 loxP/loxP 3 K5-CrePR1) 3 in parallel with Cre-negative controls (CnB1 loxP/loxP ). Keratinocyte grafting assays were performed as described previously 29 . Intradermal tumorigenicity assays were adapted from hair follicle reconstitution assays 30 . Detailed conditions for these assays as well as chromatin immunoprecipitation, immunoblotting, immunofluorescence, senescence b-galactosidase staining, biotinylated DNA pull down assays, and sorting can be found in the Method section and Supplementary  Figure legends .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Cell culture, viruses and human samples. Culturing of primary human keratinocytes and SCC13 cells, and infection with retroviruses expressing the H-ras V12 (ref. 31) , Atf3 (ref. 32 ) and constitutively active Nfatc1 (ref. 19 ) genes, together with corresponding controls, were as reported previously 29 . CsA (Sigma) was dissolved in ethanol and stored in stock solution (20 mM) at 280 uC. The VIVIT and VEET peptides were chemically synthesized by the peptide core facility of the University of Lausanne, HPLC-purified (.95% purity), dissolved in dimethylsulphoxide (DMSO) and stored in stock solution (20 mM) at 280 uC.
For knockdown experiments, cells were transfected as described 33 with validated stealth siRNAs for the human p53, CnB1 and Nfatc1 genes (Invitrogen) and for Atf3 (GeneGlobe, Qiagen) in parallel with corresponding scrambled siRNA controls, and analysed 72 h after transfection. The sequence of all siRNAs is shown in Supplementary Table 1 .
HKCs were treated with cycloheximide (10 mg ml 21 ) or ethanol vehicle alone, followed 2 h later by treatment with either CsA or VIVIT. Cells were collected at subsequent times for mRNA analysis by real time RT-PCR. Preliminary experiments (based on immunoblot analysis) showed .90% protein synthesis inhibition in HKCs treated with cycloheximide at these concentrations.
Human skin samples were obtained from abdominoplasty procedures at Massachusetts General Hospital (Boston, Massachusetts, USA) with patients' and institutional approvals and cultured as described previously 10 plus/minus treatment with CsA for 48 h. For RNA collection, skin samples were placed in preheated PBS at 60 uC for 45 s, then chilled (on ice) in 0.1 M PBS for 1 min, followed by mechanical separation of epidermis and dermis. The epidermis was homogenized in TRI Reagent (Sigma) for RNA preparation.
Squamous cell carcinoma samples were obtained at the Department of Dermatology of the Zurich University Hospital Switzerland from clinical biopsies. Parts not needed for histological diagnosis were further processed with institutional review board approval. Quantitative real time RT-PCR, chromatin immunoprecipitation and immunodetection techniques. Conditions for real time RT-PCR analysis, immunoblotting, immunofluorescence, FACS analysis and Magnetic Cell Sorting (MACS) were as described previously 24, 29, 34 . The list of gene-specific primers is provided in Supplementary Table 2 . We used the following antibodies: rabbit antiserum against human keratin 1 (PRB-149p) and loricrin (PRB-145p) (Covance); mouse monoclonal against p53 (#2524), rabbit polyclonal against c-Fos (#4384) (Cell Signaling); concentrated mouse monoclonal ((7A6)X, SC-7294) and rabbit polyclonal against NFATC1 ((H-110)X, sc-13033), rabbit polyclonal against ATF-3 (C-19, sc188), mouse monoclonal against p21 (sc-187), rabbit polyclonal against c-Jun (H-79, sc-1694) (Santa Cruz Biotechnology); rabbit polyclonal anti-human ATF3 (LS-B329) (Lifespan Bioscience); mouse monoclonal anti-pan-keratin (AE11AE3, ab961-6), rabbit anti-human vimentin (ab45939), rabbit polyclonal anti-cytokeratin 5 (ab24647), rabbit monoclonal anti-Ki67 (ab16667) (Abcam); mouse monoclonal anti-calcineurin B1 (CN-B1), mouse monoclonal anti-c-Tubulin (GTU88) (Sigma). For FACS analysis: mouse anti-CD71 allophycocyanin (APC)-conjugated and rat anti-integrin a6 fluorescein isothiocyanate (FITC)-conjugated (CD49f) (from BD bioscience), and for MACS: mouse anti-CD133 and anti-mouse IgG beads (Miltenyi Biotec). Senescence b-galactosidase staining. Senescence b-galactosidase (SA-b-Gal) activity was assessed by use of a commercially available chromogenic assay kit (Cell Signalling), according to the manufacturer's recommendations. Assays for endogenous b-galactosidase activity at a suboptimal pH (pH 6), which is thought to reflect increased lysosomal activity in senescent cells 17 were performed in parallel with similar assays at optimal pH (pH 4), as positive control for b-galactosidase activity in cells, irrespective of their growing or senescent state. Tissue arrays. Biopsies of cutaneous SCCs from patients under CsA treatment and control patient population were collected for tissue array preparation, followed by immunohistochemical analysis of ATF3 protein expression using polyclonal rabbit anti-human ATF3 antibody (Atlas Antibodies) and 10 M citrate buffer at pH 6.0 as an antigen retrieval. Tumour specimens were distinguished into in situ and invasive squamous cell carcinoma (SCC) of the skin. The numbers of analysed samples are: 126 invasive SCCs from immunocompetent patients and 127 from CsA-treated patients; 18 in situ SCCs from immunocompetent patients and 16 from CsA-treated patients. Statistical analysis indicated that the differences in ATF3 nuclear staining between tumours from CsA-treated and untreated patients was highly significant for both in situ SCCs (P , 0.05) and invasive SCCs (P , 0.01), and for the two groups combined (P , 0.001). ATF3 pull-down assays. Conditions for these assays were as described previously 35 . Briefly, HKCs were treated with either CsA (5 mM) or VIVIT (2 mM) or corresponding controls for 24 h, followed by lysis in HKMG buffer (10 mM HEPES pH 7.9, 100 mM KCl, 5 mM MgCl 2 , 10% glycerol, 1 mM dithiothreitol (DTT), 0.1% Nonidet P-40) with a mixture of protease inhibitors. Cell extracts were incubated with 1 mg of biotinylated double-strand oligonucleotides for 16 h. Two biotinylated oligonucleotide sequences of the p53 promoter containing fully conserved ATF3 binding sites (p53-1 and p53-2, corresponding, respectively, to nucleotide positions 2420 to 2358 and 22105 to 22039 from the initiation codon) in parallel with a mutated oligonucleotide of the first sequence (mp53-1), with internal nucleotide substitutions disrupting the ATF3 binding site. The oligonucleotide sequences are provided in Supplemental Table 3 . DNA-protein complexes were collected by precipitation with streptavidin-agarose beads (Pierce) for 1 h, washed three times with HKMG buffer, followed by processing for standard immunoblot analysis with anti-ATF3 antibody. Tumorigenicity assays. Mice with the CnB1 gene flanked by loxP sites and a Cre transgene driven by a keratinocyte-specific promoter (CnB1 loxP/loxP 3 K5-CrePR1) 3 in parallel with transgene-negative controls (CnB1 loxP/loxP ) were subjected to a multistep skin carcinogenesis protocol as described previously 36 . Briefly, mice (8-weeks-old; 12-16 animals per group) were treated with 7,12dimethylbenz [a] anthracene (DMBA) (20 mg in 200 ml acetone), followed by repeated treatments (twice a week) with 12-O-tetradecanoylphorbol 13-acetate (TPA) (10 24 M in acetone) for 2 months. Mice were examined throughout the duration of the experiments for papilloma versus carcinoma formation by macroscopic examination and palpation of the tumour base, to determine the onset of an invasive pattern of growth as well as infiltration of the surrounding tissues.
For grafting assays, HKCs were infected with a H-ras V12 -transducing retrovirus (LZRS-ras V12 ) 31 and, 16 h after infection, grafted onto the back of immunocompromised (Scid) mice (2 3 10 6 cells per graft) by use of dome-shaped transplantation chambers as described previously 29, 37, 38 . Mice were subsequently treated, three times a week, with CsA (via injection into the transplantation chamber; 20 mg per gram body weight, in ethanol), or ethanol vehicle alone (four mice per group). Mice were killed after 8 weeks for retrieval of the grafted tissue and histological analysis.
For intradermal tumorigenicity assays, HKCs, SCC12 and SCC13 cells were brought into suspension, and injected (10 6 cells per injection, two side flank injections per mouse) at the dermal-epidermal junction of 8-weeks-old female mice (NOD/SCID or NOD/SCID with interleukin-2 receptor gamma chain null mutation (Il2rg 2/2 ; ref. 22 ), using a procedure described previously for hair reconstitution assays 30 . Starting 24 h later, mice were given intraperitoneal injections, every other day, of CsA (20 mg per gram body weight in ethanol) or FK506 (2 mg per gram body weight in DMSO) in parallel with vehicles alone, or the VIVIT and VEET control peptides (10 mg per gram body weight in ethanol), and killed at the indicated times after cell injections.
As an alternative approach to drug treatment, HKCs or SCC cells were transfected with siRNAs against the indicated genes or scrambled siRNA controls (100 nM siRNA in HiPerFect transfection reagent, Qiagen) for 12 h before infection with the H-ras V12 transducing retrovirus. Twenty hours later, cells were trypsinized and injected into mice. In all cases, mice were killed at 10 days after cell injections and the nodules found at the site of injections processed for histological analysis.
For serial dilution tumorigenicity assays, sorted H-ras V12 -expressing HKCs or SCC cells were serially diluted, admixed in various numbers with a fixed amount of HKCs (2 3 10 5 cells per injection), mixed with Matrigel (BD biosciences), and injected into the dermal-epidermal junction of NOD/SCID or NOD/ SCID(Il2rg 2/2 ) 22 mice. Mice were killed 4 weeks later and nodules found at the site of injections processed for histological analysis.
Secondary tumorigenicity assays were performed as described 34 . Briefly, primary tumours formed by H-ras V12 -expressing HKCs or SCC cells in mice plus/minus CsA treatment were isolated, 6 weeks after cell injection, and dissociated into single cells by collagenase digestion (0.35% solution in HBSS; Sigma) for 45 min at 37 uC. After filtering of the cell suspension, recovered cells were washed with keratinocyte medium, counted and admixed in various numbers with a fixed amount of HKCs (2 3 10 5 cells) before injection at the dermal-epidermal junction of NOD/SCID mice. Four weeks after injection, mice were killed for histological analysis. Similar experiments were performed with freshly dissociated cells from primary tumours formed by H-ras V12 -expressing HKCs or SCC13 cells plus/minus increased ATF3 expression.
